RASSF1 and neoplasm: Identification of the core hippo pathway by proteomics has revealed the main direct activators of MST kinases to be SAV1 and RASSFs [2], which although infrequently mutated in cancers [3] have germline and epigenetic alterations, particularly in RASSF1A, that accelerate tumor onset and increase tumorigenicity [4, 5].